HC Wainwright reaffirmed their buy rating on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) in a research ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) had its price target decreased by investment analysts at Robert W.

(NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth ...

The company has begun testing its LSD-based anxiety treatment in late-stage trials as it builds toward potential FDA approval ...

Mind Medicine Inc. ( ($MNMD) ) has released its Q4 earnings. Here is a breakdown of the information Mind Medicine Inc. presented to its investors.

Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...

(NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a study approval ...